Eli Lilly and Company $LLY Shares Sold by Waterway Wealth Management LLC

Waterway Wealth Management LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 41.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,008 shares of the company’s stock after selling 722 shares during the period. Waterway Wealth Management LLC’s holdings in Eli Lilly and Company were worth $1,083,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. 10Elms LLP lifted its position in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares during the period. M.E. Allison & CO. Inc. lifted its position in Eli Lilly and Company by 0.7% in the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock worth $1,587,000 after purchasing an additional 10 shares during the period. Tanager Wealth Management LLP lifted its position in Eli Lilly and Company by 2.6% in the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after purchasing an additional 10 shares during the period. Morey & Quinn Wealth Partners LLC lifted its position in Eli Lilly and Company by 1.5% in the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock worth $710,000 after purchasing an additional 10 shares during the period. Finally, Wealthspan Partners LLC lifted its position in Eli Lilly and Company by 0.5% in the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after purchasing an additional 10 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced it is acquiring 4E Therapeutics, a developer of non-opioid pain treatments, expanding beyond obesity and diabetes into the large painkiller market. Investors may view the deal as a strategic move to diversify Lilly’s pipeline and create another long-term growth driver. Lilly buys non-opioid pain drugmaker 4E
• Positive Sentiment: The company also advanced several early-stage programs, including an oral candidate, an Alzheimer’s drug, and other clinical trial updates, which suggests Lilly continues to deepen its pipeline beyond its blockbuster GLP-1 franchise. Eli Lilly Advances New Oral Candidate With Fresh Phase 1 Bioavailability Study
• Positive Sentiment: Broader sector and market commentary remains constructive for GLP-1 leaders like Lilly, with reports projecting strong long-term growth in the global GLP-1 receptor agonist market. Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035
• Neutral Sentiment: Healthcare stocks were broadly firmer in afternoon trading, which may be providing a small tailwind for Lilly alongside the company-specific news. Sector Update: Healthcare Stocks Advance in Afternoon Trading
• Negative Sentiment: Some headlines point to competitive pressure from Novo Nordisk and concerns that Lilly’s GLP-1 drugs could face new reimbursement or demand headwinds, which could temper enthusiasm if those risks grow. Eli Lilly’s hottest drugs face a quiet new threat

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,122.47 on Wednesday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,182.73. The stock has a fifty day moving average of $1,006.08 and a 200-day moving average of $1,016.63. The company has a market capitalization of $1.06 trillion, a PE ratio of 39.87, a price-to-earnings-growth ratio of 1.23 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the firm earned $3.34 EPS. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, May 15th. Eli Lilly and Company’s payout ratio is 24.58%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on LLY. Leerink Partners set a $1,119.00 target price on Eli Lilly and Company in a research report on Tuesday, May 26th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 6th. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Finally, Bank of America upped their target price on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,227.74.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.